Prevalence of Acinetobacter spp. in Intensive Care Units of Selective Hospitals at Khartoum State, Sudan

Salma Y Mukhtar^1, , Mohamed M Hassan² and Isam M Elkhidir³

¹Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Neelain University

²Department of Molecular Biology and Bioinformatics, 7 Vision Training and Development Center, Khartoum Sudan

³Departments of Microbiology and Parasitology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan

Cite this paper:
Salma Y Mukhtar, Mohamed M Hassan and Isam M Elkhidir. Prevalence of Acinetobacter spp. in Intensive Care Units of Selective Hospitals at Khartoum State, Sudan. American Journal of Microbiological Research. 2022; 10(1):1-5. doi: 10.12691/ajmr-10-1-1

Abstract

Multidrug resistant (MDR) Acinetobacter spp. has emerged as an important cause of nosocomial infections with increased morbidity and mortality, evidently frequent in intensive care unit (ICU). The unique environment of ICU, artificial ventilation and other invasive procedures, exposure to antibiotics, colonization pressure, and underlying illness facilitate the spread of this species in ICU. Microbiological culture and antibiotic susceptibility testing was considered as one of the proper methods to assess the magnitude of this problem This study aimed to evaluate the prevalence and antimicrobial resistance profile of Acinetobacter spp. in selective hospital’s intensive care units of Khartoum state, Sudan. A total of 980 different types of samples were processed by routine microbiological investigation and Antimicrobial susceptibility testing of the Acinetobacter isolates was performed by the disk diffusion method as recommended by Clinical Laboratory and Standards Institute CLSI. Samples were then confirmed as Acinetobacter spp. by using PCR. As a result, consecutive non duplicate 77 Acinetobacter sp. were isolated out of a total 340 pathogenic Gram negative isolates (22.6 % prevalence). Cephalosporins, aminoglycoside, fluoroquinolones and carbapenems are becoming completely ineffective while colistin was the only effective choice.

Keywords:
Acinetobacter spp. ICU Antimicrobial resistance PCR

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Chittawatanarat K, Jaipakdee W, Chotirosniramit N, et al. Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit. Infect Drug Resist 2014; 7: 203e10.
[2]	Beijerinck MW. Uber Pigmentbildung bei Essigbakterien. Cent Bakteriol Parasitenk 1911; 29: 169-76.
[3]	Eveillard M, Kempf M, Belmonte O, et al. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. Int J Infect Dis 2013; 17(10): 802e5.
[4]	Oh YJ, Song SH, Baik SH, et al. A case of fulminant communityacquired Acinetobacter baumannii pneumonia in Korea. Korean J Intern Med 2013; 28(4): 486e90.
[5]	Kim UJ, Kim HK, An JH, et al. Update on the epidemiology treatment, and outcomes of carbapenem-resistant Acinetobacter infections. Chonnam Med J 2014 Aug; 50(2): 37e44.
[6]	Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of b-lactam antimicrobial resistance and epidemiology of major communityand healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev 2014 Nov; 78:3e13.
[7]	Nhu NT, Lan NP, Campbell JI, et al. Emergence of carbapenemresistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. J Med Microbiol 2014 Oct; 63(10):1386e94.
[8]	Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gramnegative rods. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of clinical microbiology. 9th ed. Washington, DC: ASM Press, 2007: 770-802.
[9]	Getchell-White SI, Donowitz LG, Groschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989; 10: 402-407.
[10]	Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-165 [PMID: 8964033].
[11]	Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol 1987; 138: 569-578.
[12]	Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73: 355-363.
[13]	Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23: 332-39.
[14]	Sung JY, Kwon KC, Park JW, Kim YS, Kim JM, Shin KS, et al. Dissemination of IMP-1 and OXA type b-lactamase in carbapenem-resistant Acinetobacter baumannii Korean J Lab Med 2008; 28: 16-23.
[15]	Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN. Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter sp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemoth 2009; 63: 55-59. Organization WHO. WHO Publishes List of Bacteria for which New Antibiotics are urgently needed. (WHO, Geneva, 2017). http://www.who.int/mediacentrenews/releases/2017bacteriaantibiotics needed/en/.
[16]	Nation, R. L. et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect. Dis. 15, 225-234 (2015).
[17]	Qureshi, Z. A. et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin. Infect. Dis. 60, 1295-1303 (2015).
[18]	McConnell, M. J., Actis, L., and Pachon, J. (2013). Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. Rev. 37, 130-155.
[19]	Muntasir I. Omer, Samia A. Gumaa1, Abdullatif A. Hassan2, Khaled H. Idris2, Osama A. Ali3, Mustafa M. Osman2, Mahmmoud S. Saleh2, Nagla A. Mohamed2, Mustafa M. Khaled, Prevalence and Resistance Profile of Acinetobacter baumannii Clinical Isolates from a Private Hospital in Khartoum, Sudan, American Journal of Microbiological Research, 2015, Vol. 3, No. 2, 76-79, February 2015.
[20]	Einas A Ibrahin, Nagwa EAl-Amin, High prevalence of multidrug resistant Acinetobacter species in Khartoum Intensive Care Units (ICUs), American Journal of Research Communication, Osman, et al., 2015: Vol 3(2).
[21]	Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA.A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harboring multiple plasmids. Indian J Med Res: 2008; 128: 178-187.
[22]	Jean U, Mohammed F, Abdelhay L, Fatna B. Bouchra B, Adil M, Souhail D, Lahcen B, Abdelouahed B, Charki H, Lhoussain L, Azeddine I, Mostafa E, Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units, Pan African Medical Journal – ISSN: 1937-8688.
[23]	AbdAllah S et al., Nosocomial infections and their risk factors at Mubarak Al-Kabeer hospital, Kuwait. Medical Journal of Cairo University, 2009, 78: 123-131.
[24]	Al Johani SM1, Akhter J, Balkhy H, El-Saed A, Younan M, Memish Z. Prevalence of antimicrobial resistance among gramnegative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia. Ann Saudi Med.: 2010; 30: 364-369.
[25]	Forbes BA, Sahm DF, Weissfeld AS. Bloodstream infections. In: Wilson L, editor. Bailey and Scott's Diagnostic Microbiology, 12 th ed. St Louis: The Mosby Company; 2007; 778-97.
[26]	Jaggi, Namita; Sissodia, Pushpa; Sharma, Lalit, Acinetobacter baumannii isolates in a tertiary care hospital: J Microbiol Infect Dis: 2012; 2 (2) p 57.
[27]	Wayne, PA: Clinical and Laboratory Standards Institute; 2011. CLSI. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement. CLSI document M100-S21. Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative gram-negative rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of Clinical Microbiology. Washington, DC: ASM Press, 2007; 8: 770-779.
[28]	Konkel, M. E.,Gray , , S. A., Kim, B. J., Garvis, S. G. and YOON, J,1999. Identification of the enteropathogens Campylobacter jejuni and Campylobacter coli based on the cadF virulence gene and its product, Joumal of Clinical Microbiology, 37,510-517.
[29]	Alessandra E Ferreira, Desirée P Marchetti, Molecular characterization of clinical multiresistant isolates of Acinetobacter sp. from hospitals in Porto Alegre, state of Rio Grande do Sul, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 44(6): 725-730.
[30]	Huang CH, Lee CL, ACM Lin, Chen WY, Teng PC, Lee SH, Hsieh YJ, Jang TN. Different strains of Acinetobacter baumannii spreading in an intensive care unit. JACME. 2011; 1: 5-10. PubMed | Google Scholar.
[31]	Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis. 2010; 51(1):79–84.PubMed | Google Scholar.
[32]	Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, Lim JE, Lee SK, Lee SH, Lee KJ, Kang YA, Kim SK, Chang J, Kim YS. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 2010; 10:228. Google Scholar.
[33]	J Uwingabiye, M Frikh, A Lemnouer, F Bssaibis, B Belefquih, A Maleb, S Dahraoui, L Belyamani, A Bait, C Haimeur, L Louzi, A Ibrahimi, M Elouennass, Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units, Pan African Medical Journal ISSN: 1937-8688 (www.panafrican-med-journal.com).
[34]	Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. Int J Infect Dis. 2012; 16(11):e811-e815. PubMed | Google Scholar.
[35]	Özgür ES, Horasan ES, Karaca K, Ersöz G , Atis S N, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes. Am J Infect Control. 2014; 42:206-8. PubMed | Google Scholar.
[36]	Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yagci M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: Risk factors and impact on mortality. J Crit Care. 2011; 26(5):460-467. PubMed | Google Scholar.
[37]	García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, Gili-Miner M. Risk Factors for Acinetobacter baumannii Nosocomial Bacteremia in Critically Ill Patients:a Cohort Study. Clin Infect Dis. 2001; 33(7): 939-46. PubMed | Google Scholar.
[38]	Lahsoune M, Boutayeb H, Zerouali K, Belabbes H, El Mdaghri N. Prévalence et état de sensibilité aux antibiotiques d’Acinetobacter baumannii dans un CHU marocain. Med Mal Infect. 2007; 37 :828-831.PubMed | Google Scholar.
[39]	Jaggi N, Sissodia P, Sharma L. Acinetobacter baumannii isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. J Microbiol Infect Dis. 2012; 2(2): 57-63. PubMed | Google Scholar.
[40]	Nazmul MHM, Jamal H, Fazlul MKK. Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Biomed Res-India. 2012; 23 (4): 571-575. PubMed | Google Scholar.
[41]	Obeidat N, Jawdat F, Al-Bakri AG, Shehabi AA. Major biologic characteristics of Acinetobacter baumannii isolates from hospital environmental and patients’ respiratory tract sources. Am J Infect Control. 2014; 42(4):401-4. PubMed | Google Scholar.
[42]	Shields RK, Kwak EJ, Potoski BA, Doi Y, Adams-Haduch JM, Silviera FP, Toyoda Y, Pilewski JM, Crespo M, Pasculle AW, Clancy CJ, Nguyen MH. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011; 70(2): 246-252. PubMed | Google Scholar.
[43]	Xu J, Sun Z, Li Y, Zhou Q. Surveillance and Correlation of Antibiotic Consumption and Resistance of Acinetobacter baumannii complex in a Tertiary Care Hospital in Northeast China, 2003–2011. Int J Environ Res Public Health. 2013; 10: 1462-1473. PubMed | Google Scholar.
[44]	Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(10): 3471-84. PubMed | Google Scholar.
[45]	Ziglam H, Elahmer O, Amri S, Shareef F, Grera A,Labeeb M, Zorgani A. Antimicrobial resistance patterns among Acinetobacter baumannii isolated from burn intensive care unit in Tripoli, Libya. IAJAA. 2012; 2 (3): 1-8. PubMed | Google Scholar.
[46]	Deepti Rawat and Deepthi Nair, Extended-spectrum β lactamases in Gram Negative Bacteria J Glob Infect Dis. 2010 Sep-Dec; 2(3): 263-274.